Press release
Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Players are AXIM Biotechnologies, Lundbeck, OTSUKA PHARMACEUTICAL S.A., Pfizer, Bionomics Ltd
Post-Traumatic Stress Disorder (PTSD) Therapeutics -Pharma Proff
Download the sample report at: https://www.pharmaproff.com/request-sample/1238
PTSD is not diagnosed unless the symptoms last for at least one month. In order to be diagnosed with PTSD, a person must have three different types of symptoms: re-experiencing symptoms, avoidance and numbing symptoms, and arousal symptoms. Cognitive behavioral therapy (CBT) and family therapy are some of the therapies used to treat PTSD. ZOLOFT (by Pfizer Inc.), a selective serotonin reuptake inhibitor (SSRI), is being used for the treatment of PTSD.
Get the detailed analysis at: https://www.pharmaproff.com/report/ptsd-therapeutics-pipeline-analysis
According to the research findings, majority of the pipeline drug candidates are being developed to be administered by oral route. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for PTSD through oral route has shown promising results in clinical studies.
Companies that are involved in developing therapeutics for PTSD have shown positive clinical results in the various phases of drug development. For instance, BNC210, a negative allosteric modulator of the A7 nicotinic acetylcholine receptor, is being developed by Bionomics Limited to treat patients with PTSD. The results from the phase II trial of BNC210 showed that BNC210 was safe and well tolerable in patients with PTSD.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1238
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co. Ltd. (Otsuka) entered into an agreement to develop and commercialize five innovative products in the field of psychiatry and neuroscience. In November 2018, Lundbeck and Otsuka reported positive phase II data from the combination treatment of brexpiprazole and sertraline for the treatment of PTSD.
Bionomics Limited, Pfizer Inc., India Globalization Capital Inc., Therapade Technologies LLC, Axim Biotechnologies Inc., H. Lundbeck A/S, and Otsuka Pharmaceutical Co. Ltd. are some of the major companies involved in the development of drug candidates for the treatment of PTSD.
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of PTSD. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the PTSD therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to PTSD.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Players are AXIM Biotechnologies, Lundbeck, OTSUKA PHARMACEUTICAL S.A., Pfizer, Bionomics Ltd here
News-ID: 1777624 • Views: …
More Releases for PTSD
Interactive Game Art "TUNE" Reveals Elephants' PTSD as War's Silent Victims
"Did I just kill that elephant? I just did what I normally do in games."
Image: https://www.globalnewslines.com/uploads/2025/09/e22fd917ec2fe862c3c4ee22520bf08a.jpg
This was the reaction of a visitor at the game art exhibition Tune, held from August 4 to 11 in Seongsu-dong, Seoul. The realization came only after they reflexively pulled the trigger the moment a target appeared; what they had shot was an elephant resting within its family herd.
Developed over the course of a…
Burch Tree Counseling Center Now Offering EMDR Therapy for PTSD and Trauma
Burch Tree Counseling Center is proud to announce the addition of Eye Movement Desensitization and Reprocessing (EMDR) therapy to its services, providing a powerful tool for individuals struggling with Post-Traumatic Stress Disorder (PTSD) and trauma.
As an evidence-based treatment recognized by organizations such as the American Psychological Association (APA) and the Department of Veterans Affairs (VA), EMDR therapy is designed to help clients process and heal from distressing memories. Unlike traditional…
Post Traumatic Stress Disorder (PTSD) Market Report and Forecast 2024-2032
The post-traumatic stress disorder (PTSD) market size is expected to grow at a CAGR of 5.4 % during the forecast period of 2024-2032 in the major markets, driven by increasing prevalence of post-traumatic stress disorder (PTSD), along with reducing stigma around mental health conditions.
Post Traumatic Stress Disorder (PTSD):
Post Traumatic Stress Disorder (PTSD) is a mental health condition triggered by experiencing or witnessing a terrifying event. Symptoms include flashbacks, nightmares, severe…
Post Traumatic Stress Disorder (PTSD) Therapeutics Market Value Expected to Expa …
Post Traumatic Stress Disorder (PTSD) Therapeutics Market is expected to witness moderate growth registering 4.4% CAGR during the forecast period (2023-2029).
By observing alternative approaches, this Post Traumatic Stress Disorder (PTSD) Treatment Market research report aims to analyze the sales force for distribution of goods. It helps key players reduce investment risk by providing relevant data and business considerations. Key organizations can easily get a clear view of current market…
PTSD Exhibits Emerging Pipeline with 23 Drug Candidates
The study analysed that the PTSD pipeline comprises of 23 drug candidates, of which one drug candidate is in the Phase III stage of development, two drug candidates are in the Phase II stage of development, seven drug candidates are in the Pre-Clinical stage of development, two drug candidates are in Discovery stage, one drug candidate is in Unknown Clinical stage, one drug candidate is in the Discontinued stage and…
Donald Trump And PTSD: PTSD Is Not A Sign Of Weakness Says June Sitler, Author O …
PTSD can take many forms. When one hears Post Traumatic Stress Disorder (PTSD) the image of a Vietnam Vet comes to mind. However, many people from all walks of life may suffer from this disorder. They are the survivors. They can be people who live in the inner city, those who have suffered the loss of a loved one, survivors of childhood trauma in adulthood, or a man or woman…
